MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
NEW YORK, Dec. 01, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Osiris Therapeutics, Inc. (NASDAQ:OSIR) securities between May 12, 2014 and November 20, 2015.
Click here to learn about the case: http://docs.wongesq.com/OSIR-Info-Request-Form-1014. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Osiris Therapeutics you have until January 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/OSIR-Info-Request-Form-1014.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
